Gixam System for Colorectal Cancer Screening

The trial aims to evaluate a new device called the Gixam System, which screens for colorectal cancer by detecting pre-cancer or cancer in the colon and rectum. Researchers seek to determine if the Gixam test is effective and safe, particularly for individuals who have had a negative result on a Fecal Immunochemical Test (FIT). Participants will undergo the Gixam test, a home FIT, and a standard colonoscopy for comparison. This study may suit those aged 45-84 who are at average risk for colorectal cancer and are scheduled for a routine colonoscopy.

As an unphased trial, it offers participants the chance to contribute to important research that could enhance early detection methods for colorectal cancer.

You may need to stop taking certain medications like antibiotics, anti-fungal medications, anti-inflammatories, or probiotics 14 days before the Gixam test. The trial does not specify other medications, so check with the study team for more details.

Research has shown that the Gixam System is a non-invasive test using AI technology to detect early signs of colorectal cancer. It targets precancerous growths, known as adenomas, before they develop into cancer. As a non-invasive test, it does not involve surgery or entering the body, thus carrying no direct medical risks.

Researchers are excited about the Gixam System for colorectal cancer screening because it combines multiple screening methods—Gixam test, FIT (Fecal Immunochemical Test), and colonoscopy—into a single streamlined process. Unlike traditional methods that often rely on just one approach, this system enhances accuracy by cross-verifying results from different tests. This comprehensive strategy could potentially improve early detection rates, catching cancer in its early stages when it's most treatable.

Research has shown that the Gixam System might detect early signs of cancer in the colon and rectum, particularly in individuals with a negative Fecal Immunochemical Test (FIT) result. In this trial, all participants will undergo the same intervention, which includes the Gixam test, FIT, and screening colonoscopy. The aim is to detect cancer early, even when other tests might not. While solid evidence on Gixam's effectiveness is still being gathered, the focus remains on its potential to identify cancer that other screenings might miss. This could enhance early detection and treatment options for colorectal cancer.¹⁶⁷⁸⁹